摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,5-双(三氟甲基)氢化肉桂酸 | 302912-03-4

中文名称
2,5-双(三氟甲基)氢化肉桂酸
中文别名
2,5-双(三氟甲基)苯丙酸;3-[2,5-双(三氟甲基)苯基]丙酸
英文名称
3-(2,5-bis(trifluormethyl)phenyl)propionic acid
英文别名
2,5-Bis(trifluoromethyl)hydrocinnamic acid;3-[2,5-bis(trifluoromethyl)phenyl]propanoic acid
2,5-双(三氟甲基)氢化肉桂酸化学式
CAS
302912-03-4
化学式
C11H8F6O2
mdl
——
分子量
286.174
InChiKey
CHIXRVUEUZNLNI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    33-43 °C (lit.)
  • 沸点:
    268℃
  • 密度:
    1.427
  • 闪点:
    116℃
  • 稳定性/保质期:
    常温常压下稳定,应避免与强氧化剂接触。

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    19
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    8

安全信息

  • 危险品标志:
    Xn
  • 安全说明:
    S26,S36/37,S7
  • 危险类别码:
    R40,R36/37/38,R20
  • 海关编码:
    2916399090
  • WGK Germany:
    3

反应信息

  • 作为反应物:
    描述:
    1H-苯并咪唑-6-酰肼2,5-双(三氟甲基)氢化肉桂酸三氯氧磷 作用下, 以2.1%的产率得到5-(5-(2,5-bis(trifluormethyl)phenylethyl)-1,3,4-oxadiazol-2-yl)benzimidazole
    参考文献:
    名称:
    Structure–Activity Relationships of Benzimidazole-Based Glutaminyl Cyclase Inhibitors Featuring a Heteroaryl Scaffold
    摘要:
    Glutaminyl cyclase (hQC) has emerged as a new potential target for the treatment of Alzheimer's disease (AD). The inhibition of hQC prevents of the formation of the A beta(3(pE)-40,42) species which were shown to be of elevated neurotoidcity and are likely to act as a seeding core, leading to an accelerated formation of A beta-oligomers and fibrils. This work presents a new class of inhibitors of hQC, resulting from a pharmacophore-based screen. Hit molecules were identified, containing benzimidazole as the metal binding group connected to 1,3,4-oxadiazole as the central scaffold. The subsequent optimization resulted in benzimidazoly1-1,3,4-thiadiazoles and -1,2,3-triazoles with an inhibitory potency in the nanomolar range. Further investigation into the potential binding mode of the new compound classes combined molecular docking and site directed mutagenesis studies.
    DOI:
    10.1021/jm4001709
点击查看最新优质反应信息

文献信息

  • [EN] TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE TETRAHYDRO-ISOQUINOLYL-ACETAMIDE DESTINES A SERVIR D'ANTAGONISTES DES RECEPTEURS D'OREXINE
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2004085403A1
    公开(公告)日:2004-10-07
    The invention relates to novel acetamide derivatives of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.
    该发明涉及公式(I)的新型乙酰胺衍生物及其在制备药物组合物中作为活性成分的用途。该发明还涉及相关方面,包括制备这类化合物的方法、含有其中一个或多个这类化合物的药物组合物,特别是它们作为促进睡眠的药物受体拮抗剂的用途。
  • Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
    申请人:Aissaoui Hamed
    公开号:US20060178515A1
    公开(公告)日:2006-08-10
    The invention relates to novel acetamide derivatives of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.
    本发明涉及一种新的醋酰胺衍生物(I式),以及它们作为制备药物组成部分的活性成分的用途。本发明还涉及相关方面,包括制备这些化合物的过程,含有这些化合物中的一种或多种的药物组成物,特别是它们作为促进睡眠的药物组成物中的使用,其中它们作为促进睡眠的药物组成物的奥力昔康受体拮抗剂。
  • PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS
    申请人:Gschneidner David
    公开号:US20110046050A1
    公开(公告)日:2011-02-24
    The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.
    本发明提供苯基烷基羧酸化合物及含有此类化合物的组合物,有助于传递生物活性物质。
  • NOVEL INHIBITORS
    申请人:HEISER Ulrich
    公开号:US20110224259A1
    公开(公告)日:2011-09-15
    The invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    本发明涉及新型杂环衍生物,作为谷氨酰环化酶(QC,EC 2.3.2.5)的抑制剂。QC催化N-末端谷氨酰残基的分子内环化成吡咯谷氨酸(5-氧代脯氨酰,pGlu*),释放氨,并将N-末端谷氨酸残基分子内环化成吡咯谷氨酸,释放水。
  • Inhibitors of glutaminyl cyclase
    申请人:Heiser Ulrich
    公开号:US09181233B2
    公开(公告)日:2015-11-10
    The invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    本发明涉及新型杂环衍生物作为谷氨酰环化酶(QC,EC 2.3.2.5)抑制剂。QC催化N-末端谷氨酰残基的分子内环化成为吡二酰基酸(5-氧代脯氨酰残基,pGlu *),释放氨并将N-末端谷氨酸残基分子内环化成为吡二酰基酸,释放水。
查看更多